Novocure Limited · NASDAQ:NVCR

Novocure — Investor Presentation (July 2026)

15 slides from Novocure's investor presentation, July 2026

  1. Slide 1: July 2026

    July 2026 © 2026 Novocu re GmbH 1

  2. Slide 2: Forward-looking statements

    forward - looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding ant

  3. Slide 3: Novocure

    Effective, wearable cancer therapy device Non - invasive medical device to treat solid tumors Market leader in glioblastoma novocure Increasing penetration across major global markets unique cancer therapy Near - term expansion Multiple new indication and country launches upcoming Path to profitabil

  4. Slide 4: Tumor Treating Fields are alternating electric fields that target electrical properties of cancer cells

    Tumor Treating Fields ( TTFields ) are alternating electric fields that target the electrical properties of cancer cells TTFields 100 to 500 kHz cancer cell healthy cell Liu K, et al. (2025) Comprehensive simulations of intracellular electric fields during exposure to tumor treating fields. Front. O

  5. Slide 5: TTFields are delivered through portable medical devices

    TTFields are delivered through portable medical device s glioblastoma multiforme generator carrying case metastatic non - small cell lung cancer TTFields generator malignant pleural mesothelioma disposable locally advanced pancreatic cancer transducer arrays Device and components shown above compris

  6. Slide 6: Consistent growth across the Optune portfolio

    consistent growth across the Optune portfolio Total active patients on therapy 6,000 +18% 5,128 TOTAL ACTIVE PATIENT GROWTH Y oY* 5,000 4,331 3,963 4,000 3,571 3,000 +16% QUARTERLY NET REVENUE GROWTH YoY * 2,000 1,000 $699.2M 0 2Q 2023 2Q 2024 2Q 2025 2Q 2026 NET REVENUE TTM* U.S. Germany France Jap

  7. Slide 7: Positive phase 3 data from large, randomized trials

    positive phase 3 data from large, randomized trials DATA SUPPORTING FDA PMA APPROVALS PENDING FDA REVIEW glioblastoma non - small cell lung cancer pancreatic cancer brain metastases (NSCLC) 1.0 0.8 Probability of intracranial 0.6 SRS only (n=149) 0.4 progression SRS+TTFields (n=149) 0.2 0 0 2 4 6 8

  8. Slide 8: Key catalysts anticipated in 2026

    key catalysts anticipated in 2026 ✓ Q1 : Release topline data from Phase 2 PANOVA - 4 trial (metastatic PDAC) CLINICAL ✓ Q2 : Release topline data from Phase 3 TRIDENT trial (GBM) Q4 : Complete enrollment in Phase 3 KEYNOTE D58 trial (GBM) ✓ Q1 : Launch Optune Pax for pancreatic cancer in the U.S. C

  9. Slide 9: R&D investments focused on TTFields' unique properties to target tumors in need of a biophysical solution

    R&D investments focused on TTFields ’ unique properties to target tumors in need of a biophysical solution bypass drug delivery and modulate tumor microenvironment bioavailability barriers to promote immune recognition INCREASE TUMOR ACCESSIBILITY MAXIMIZE IMMUNOTHERAPY GBM, glioblastoma; mets , met

  10. Slide 10: Ongoing trials designed to expand TTFields reach

    glioblastoma ongoing trials designed to expand TTFields reach KEYNOTE D58 PHASE 3 TRIAL IN NEWLY DIAGNOSED GBM 1 DESIGN : TTFields + pembrolizumab + chemotherapy PATIENTS : 741 PRIMARY ENDPOINT : Overall survival LUNAR - 2 PHASE 3 TRIAL IN 1L METASTATIC NSCLC 2 DESIGN : TTFields + pembrolizumab + pl

  11. Slide 11: Strategic roadmap balancing growth and profitability

    strategic roadmap balancing growth and profitability drive scale advance pursue adoption portfolio innovation profitability in approved through new through clinical to fuel growth and indications indication launches and product shareholder value development © 2026 Novocu re GmbH 11

  12. Slide 12: Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer

    actor portrayal together with our patients, we strive to extend survival in some of the most aggressive forms of cancer Confidential © ©2025 2026 Novocu rereGmbH GmbH 12

  13. Slide 13: Optune Gio, Optune Lua and Optune Pax indications for use and important safety information

    Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information INDICATIONS FOR USE • Optune Gio ® is intended as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiform e (GBM). • Optune Gio with temozolomide i

  14. Slide 14: Optune Gio, Optune Lua and Optune Pax indications for use and important safety information

    Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information WARNINGS AND PRECAUTIONS • Optune Gio, Optune Lua, and Optune Pax can only be prescribed by a healthcare provider that has completed the required certif ica tion training provided by Novocure ® (the dev

  15. Slide 15: Optune Gio, Optune Lua and Optune Pax indications for use and important safety information (cont'd)

    Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information WARNINGS AND PRECAUTIONS (CONT’D) • The most common ( ≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab - paclitaxel were neutropenia, ane mia, thrombocytopenia, leukopenia,

Novocure — Investor Presentation (July 2026) on 6ix